VYBRIQUE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VYBRIQUE (VYBRIQUE).
Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion and lowering blood glucose. Also improves glycemic control and reduces cardiovascular risk in patients with type 2 diabetes.
| Metabolism | Primarily metabolized via glucuronidation by UGT1A9 and UGT2B7; minor CYP-mediated metabolism (CYP3A4). |
| Excretion | Primarily hepatic metabolism with <5% renal excretion of unchanged drug. Biliary/fecal elimination accounts for ~60-70% as metabolites. |
| Half-life | Terminal elimination half-life is 1.0-1.5 hours, consistent with frequent dosing requirement. |
| Protein binding | 94-96% bound to serum proteins, primarily albumin and α1-acid glycoprotein. |
| Volume of Distribution | Vd approximately 0.3 L/kg, indicating distribution primarily in extracellular fluid. |
| Bioavailability | Oral bioavailability is ~70% due to first-pass hepatic metabolism. |
| Onset of Action | Intravenous: within 5 minutes; oral: 30-60 minutes. |
| Duration of Action | Duration of action is 2-4 hours, necessitating multiple daily doses for sustained effect. |
| Molecular Weight | 472.54 |
25 mg orally once daily, titrated to 50 mg once daily after 2 weeks, then to 75 mg once daily as tolerated by ECG monitoring.
| Dosage form | FILM |
| Renal impairment | eGFR 15-29 mL/min/1.73m2: 25 mg once daily; eGFR <15 mL/min or on dialysis: not recommended. |
| Liver impairment | Child-Pugh class B: no dose adjustment required; Child-Pugh class C: not studied, contraindicated. |
| Pediatric use | Not approved for pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; monitor for QT prolongation due to age-related decline in renal function. |
| 1st trimester | No adequate human studies; animal studies show fetal risk. Avoid use in first trimester unless benefit outweighs risk. |
| 2nd trimester | Potential fetal harm; use only if clearly needed. |
| 3rd trimester | May cause fetal harm; avoid use in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for VYBRIQUE (VYBRIQUE).
| Placental transfer | Unknown; likely crosses placenta based on molecular weight and animal studies. |
| Breastfeeding | Not recommended during breastfeeding due to potential for serious adverse reactions in infants. Consider discontinuing drug or breastfeeding. |
| Lactation Rating |
■ FDA Black Box Warning
WARNING: RISK OF KETOACIDOSIS IN PATIENTS WITH TYPE 1 DIABETES AND OTHER PATIENTS WITH KETOACIDOSIS PREDISPOSITION. Vybriq should not be used in patients with type 1 diabetes mellitus. Ketoacidosis, including life-threatening cases, has been reported in patients with type 2 diabetes mellitus taking SGLT2 inhibitors. Patients with signs and symptoms of ketoacidosis should be assessed for ketoacidosis regardless of blood glucose levels.
| Serious Effects |
Hypersensitivity to vibegron or any excipientSevere uncontrolled hypertension (systolic ≥180 mm Hg or diastolic ≥110 mm Hg)History of urinary retentionGastric retentionUncontrolled narrow-angle glaucoma
| Precautions | Ketoacidosis, Volume depletion, Urosepsis and pyelonephritis, Lower limb amputation, Hypoglycemia with concurrent insulin or sulfonylurea use, Genital mycotic infections, Increased LDL-C, Acute kidney injury |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and can increase finerenone levels. No specific food restrictions otherwise. Avoid potassium-rich foods if concurrent risk of hyperkalemia (e.g., bananas, oranges, leafy greens) should be consumed with caution and monitored. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | VYBRIQUE (trofinetide) is not expected to increase the risk of major birth defects based on limited human data. In animal studies, no adverse developmental effects were observed at exposures up to 5 times the maximum recommended human dose. However, data are insufficient to rule out risks. Use during pregnancy only if clearly needed. |
| Fetal Monitoring | Monitor for maternal adverse reactions including gastrointestinal effects (nausea, vomiting, diarrhea) and potential weight loss. Fetal monitoring per standard prenatal care; no specific fetal monitoring required due to drug. |
| Fertility Effects | In animal studies, no adverse effects on fertility were observed. Human data are not available. VYBRIQUE is not expected to impair fertility in females or males. |
| Clinical Pearls | Vybriqe (finerenone) is a nonsteroidal mineralocorticoid receptor antagonist indicated for chronic kidney disease in type 2 diabetes. Monitor serum potassium closely, as hyperkalemia risk is dose-dependent. Avoid use with strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) due to increased exposure. Dose adjustments required for moderate hepatic impairment (Child-Pugh B); contraindicated in severe impairment. Can cause orthostatic hypotension; assess volume status before initiation. Combination with other antidiabetic agents may enhance hypoglycemia risk. |
| Patient Advice | Take this medication at the same time each day, with or without food. · Avoid potassium supplements and salt substitutes containing potassium unless advised by your doctor. · Report symptoms of high potassium (muscle weakness, irregular heartbeat, numbness) or low blood pressure (dizziness, fainting). · Do not use grapefruit or grapefruit juice while taking this medication. · Tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding. · Monitor your blood pressure and blood sugar regularly as directed. |